drugset
drugset / Trial / NCT05357677

To Evaluate the Efficacy and Safety of SR419 in Patients With Postherpetic Neuralgia (PHN)

NCT05357677 ↗

Phase 2 Completed 83 enrolled Shanghai SIMR Biotechnology Co., Ltd.
RandomizedCrossoverQuadruple-blindTreatment

Summary

This is a Phase II, international multicenter, double-blind, placebo-controlled, crossover study to assess the efficacy of SR419 in PHN subjects.

Timeline

Start
2022-05-13
Primary completion
2023-01-13
Completion
2023-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject SR419 Unknown 30 mg —

Indications

postherpetic neuralgia